Member Info for tomhuk2000

With regards to directors having skin in the game, I take it you don’t invest in small caps very often? So many low MCAP company’s are slated for directors not buying in.

I think whatever happens here at AGL for you FeverTree it’s a case of: Damned if you do and Damned if you don’t.

And I understand your attitude towards the company if you’ve lost a lot of money in the past or are sitting on heavy losses… If it’s the latter I hope for both our sakes it is the start of a period of prosperity for AGL.

Morning FeverTree,

Yes you’ve highlighted all of this a number of times now.

Now that efforts have been made to make Parsortix etc more commercially viable and accessible over the course of 2023, let’s see how he does in the coming months. If no success in signing deals in the next 6 months then I and most other investors will be gone (which seemingly may please you).

If not the the company is on the verge of a massive turnaround and will do very well for its investors. I have bought in because I’ve been greatly encouraged by the work done to reverse the failings you’ve highlighted from the past. Time will tell.

Here’s a Twitter thread breaking down the case for investment in AGL

Parsortix CTC Timor cell harvesting device has:

- US FDA Approval

- EU CE Mark

- UK UKCA Mark

- 26 granted patents inc USA, China, Europe, Japan, Canada & Australia until 2034

- Rights to market in USA, UK & Europe currently

Financials:

- Debt Free

- Cash in the bank of £15m = over 50% of current MCAP

- Fully funded cash runway until Q2 2025

- 2023 Revenue up 120%

- 2024 Revenue expected to treble (not including any new deals)

- Cost streamlining in place

- Directors have skin in the game & bought most recently at 28p to 29.75p (prior to this at 80p)

- Staff share options exercisable at 25.75p

- Portrait+ Kit launched last week at San Antonio Breast Cancer Symposium.

Upcoming Catalysts:

- Assay updates

- Molecular study results

- Major pharmaceutical deals (as per recent webinar)

- Due to the diverse service offering, the CEO has stated: “a single deal could be worth 100’s of millions”

Conclusion:

- Lack of commercial deals has been the main criticism. However, AGL has worked to simplify the service offering for easier commercialisation (new Portrait+ kit & molecular studies etc) Are AGL at a turning point?

https://x.com/redditdeluxe/status/1735222212985082111?s=46&t=IHEn1TE0c7FNFBktt6H8XQ

Hi Bantham,

That would be quite an extreme reaction on my part if I did. I’ve bought stock in and made money from turnaround company’s in far worse shape than AGL. Ones where profit warnings and going concern notices have been issued. In those cases I’ve done my due diligence to establish if they’re at a turning point and invested where I see potential. AGL is one of those cases.

I understand that the commercialisation of AGL’s services has been disappointing since the FDA approval. But for me to sell my entire holding based on the company taking their investor relations more “in-house” to save money and to opt to cut costs and just have a single broker, all seems a little heavy handed.

As I’ve said before, and I may come to regret it, but I’ve bought in this month and have a good average. I’ll continue to hold and give AGL the opportunity to exploit their recent developments in simplifying the route to market and get some deals signed. If in 6 months time nothing has changed, or there’s bad news along the way, I’ll reassess.

I was just about to update the board on that too.

I emailed them yesterday and had a reply from Ian Griffiths stating the same message. He also replied regarding the Investor Relations Manager stating:

“ We have previously announced that we would be carefully controlling our costs and that does mean we have to cut back in a number of areas and Investor Relations is one of those.

There was no requirement for an RNS when Andew Holder left, just as we did not issue an RNS when he joined. We have reverted to the CEO and CFO handling this, with support from others as necessary.”

To be fair, the comms via Twitter and in RNS’s since his departure has been very good.

Well FeverTree, I’ve stated my position a few times this week. I wouldn’t have bought in prior to the last few weeks, but I have seen a concerted increase in activity and I’m encouraged by the progress made with simplifying the products/service to make it more commercially accessible. So I’ve take a decent position.

I’m not saying there haven’t been past failings here, on the contrary, and that’s why I didn’t buy in and haven’t lost money here like many have. If you’re one of these individuals that have i empathise with your frustrations. But I’ve now invested and I’ll give AGL until mid 2024 at least to pull a deal out of the bag. If they do so I think more deals will come in quick succession.

I think he was replying to “TwoGoods” previous message (presumably reported and now taken down) asking: When is the next rights issue date?

Knowing full well the recent RNS stated that AGL are funded into Q2 2025, have increased revenues by 120% compared to last year and have forecasted they’ll triple revenues next year, it was the obviously a cheap attempt at winding up the board.

With other posters on here who have grievances against AGL at least they are well researched and air their issues coherently. Sadly TwoGood is here to disrupt and contributes nothing credible. Best to block or ignore and move on.

Yes just saw that. Also it confirms my recollection that he was also the boss at Berenberg… Interesting. Looks like he’s gone onto a completely new field now.

Nothing as yet. I’ll keep you posted

Let’s hope I am right as I have a rather sizable position (luckily, with a very good average) lol

“Berenberg Broker note for #AGL updated 9th November 2023.

PRICE TARGET £1.20 per share (Over 10 times the current share price)

now let’s get those commercial deals signed @Parsortix 👍🏻”

https://x.com/redditdeluxe/status/1734173155319570542?s=46&t=IHEn1TE0c7FNFBktt6H8XQ

I would agree with you Feve tree, the lack of progress from the FDA approval until now has been disappointing.

However, as I mentioned before, I feel that decent progress has been made in the streamlining and simplification of the commercialisation process of late, and that is why I chose to become a new investor here a couple of weeks ago.

My first impression of AGL closing their American site had me wondering why. However, on reflection, I am not too worried about it, given the modern global digital age in which we now find ourselves and the advancement of comms. I don’t think it’s all that necessary to have regional hubs and I’m sure that they did a great deal of costing analysis in the run-up to making the decision and found that the costs simply outweighed the benefits. I was also encouraged to see AGL attending the San Antonio symposium last week, so it would appear that the focus is still very much on the US market.

I understand (if you are, in fact, an investor), your frustrations. Now is the time where they need to make all of this progress count and convert, what is a Great bit of technology into commercial deals. I bought in as I I think that now this is very likely to happen.

Let’s hope some deals are signed before that juncture.

For transparency, I increased my holding further this morning (like to have round even numbers - OCD lol)

Just checked back through all TR1’s, yes Bailie Gifford reduced their holdings but still hold over 3% of the company. Morgan Stanley’s position appears unchanged and aegon, after buying in heavily, took a bit off the table. Frontier increased their holding further.

Normally big institutional investors have a DD MCAP requirement for investments of a minimum of £50m or often £100m MCAP. So the absence of blue chip institutional investors at this stage doesn’t worry me.

My understanding as per the last RNS is that revenue for this year is up 120% on last year and that 2024 revenue is expected to triple. The cash runway is expected to fully find AGL through to Q2 2025. This also doesn’t include revenue from any new deals.

So, your comment re the need for £20m in 12 months seems a bit inaccurate.

I’ll drop them an email to try to find out more details.

Regarding “institutional selling”. What are you referring to? The past few holdings RNS’s reported Aegon had reduced their holding, but frontier had significantly increased their stake.

But with the greatest respect that’s speculation at this point.

Just found the head of IR on LinkedIn. He was formerly CEO of Berenberg.

With regards to your comment about being “dropped by Jeffries”. Is this something you know for a fact? Or is it simply a decision ANGLE has taken to have one sole broker instead of 3?

Hi Bantham,

Do you have a link to info of the head of IR leaving?

Very positive study results from University of New Mexico on Brain Metastasis.

“The researchers used the Parsortix system to harvest CTCs for analysis and concluded that "… gene expression in CTCs could be pivotal to prescribing more targeted treatment based on the needs of the patient."

https://www.londonstockexchange.com/news-article/AGL/parsortix-unlocks-opportunities-for-drug-discovery/16245716